Standardization of flow cytometric minimal residual disease assessment in international clinical trials - a feasibility study from the European Myeloma Network

Autor: Paola Omedè, Stefania Oliva, Helle Høholt, Roman Hájek, Romana Králová, Lucie Rihova, Pieter Sonneveld, Jeroen G. te Marvelde, Davine Hofste op Bruinink, Vincent H.J. van der Velden, Milena Gilestro, Hans Erik Johnsen, Annemiek Broijl, Alexander Schmitz, Mario Boccadoro

Publikováno v: Op Bruinink, D H, Oliva, S, Rihova, L, Schmitz, A, Gilestro, M, Te Marvelde, J, Kralova, R, Høholt, H, Broijl, A, Johnsen, H E, Hajek, R, Boccadoro, M, Sonneveld, P, Omedè, P, Van der Velden, V H J & European Myeloma Network 2021, ' Standardization of flow cytometric minimal residual disease assessment in international clinical trials-a feasibility study from the European Myeloma Network ', Haematologica, vol. 106, no. 5, pp. 1496-1499 . https://doi.org/10.3324/haematol.2020.267831
Haematologica
Haematologica, Online ahe. Ferrata Storti Foundation

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::989cd01cf983d667e5ec48597387ced2
https://vbn.aau.dk/da/publications/6b55b459-ac12-40e6-b32f-442202da3758

Minimal Residual Disease (MRD) follow up of MM patients obtaining stringent complete remission (sCR) in the NMSG/EMN02 clinical trial – defining sCR numbers and prediction of disease progression by multiparametric flow cytometry (MFC)

Autor: Hans Erik Johnsen, Alexander Schmitz, Julie Støve Bødker, Sonneveld, P., Hofste Op Bruinink, D., Holt, B., Velden, V. H. J., Abildgaard, N., Ahlberg, L., Andersen, N., Andreasson, B., Brandefors, L., Christiansen, H. B., Faxoe, S., Fransson, C., Friestad, M., Gregersen, H., Hammerlund, Y., Hansson, M., Haukaas, E., Hector, M., Helleberg, C., Holst, M., Jönsson, A. K., Karlsson, V., Klostergaard, A., Kjær, S., Lauri, B., Lenhoff, S., Lonn, I., Myhr, E., Pedersen, B. H., Renna, R., Sjøgren, T. V., Asta Svirskaite, Szatkowski, D. L., Vangsted, S., Waage, A., Schjesvold, F. H., U-H, Mellqvist, Helle Høholt, Louise Hvilshøj Madsen, Henning Sand Christensen, Rasmus Brøndum, Martin Bøgsted, Karen Dybkaer

Publikováno v: Aalborg University
Johnsen, H E, Schmitz, A, Bødker, J S, Sonneveld, P, Hofste op Bruinink, D, van der Holt, B, van der Velden, V H J, Abildgaard, N, Ahlberg, L, Andersen, N, Andreasson, B, Brandefors, L, Christiansen, H B, Faxoe, S, Fransson, C, Friestad, M, Gregersen, H, Hammerlund, Y, Hansson, M, Haukaas, E, Hector, M, Helleberg, C, Holst, M, Jönsson, A K, Karlsson, V, Klostergaard, A, Kjær, S, Lauri, B, Lenhoff, S, Lonn, I, Myhr, E, Pedersen, B H, Renna, R, Sjøgren, T V, Svirskaite, A, Szatkowski, D L, Vangsted, S, Waage, A, Schjesvold, F H, Mellqvist, U-H, Høholt, H, Madsen, L H, Christensen, H S, Brøndum, R F, Bøgsted, M & Dybkær, K 2018, ' Minimal Residual Disease (MRD) follow up of MM patients obtaining stringent complete remission (sCR) in the NMSG/EMN02 clinical trial – defining sCR numbers and prediction of disease progression by multiparametric flow cytometry (MFC). ', Haematologica, vol. 103, no. S1, BA6, pp. 13 . < http://www.emn2018.com/doc/Abstract-book.pdf >

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::16f7414171447361f275e257d55088a8
https://vbn.aau.dk/en/publications/2e93ef3e-a0c1-42fd-91fc-9ee0616eb58b